LEXX Stock Overview Operates as a biotechnology company. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lexaria Bioscience Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lexaria Bioscience Historical stock prices Current Share Price US$2.30 52 Week High US$6.85 52 Week Low US$1.20 Beta 1.08 1 Month Change -14.81% 3 Month Change -27.90% 1 Year Change 65.47% 3 Year Change -46.88% 5 Year Change -81.96% Change since IPO -29.72%
Recent News & Updates
Lexaria Bioscience Corp. Begins Dosing in its Phase 1B, 12-Week Chronic Study GLP-1-H24-4 Dec 19 Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board
Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide Dec 10
Chief Executive Officer recently bought US$51k worth of stock Dec 04
Consensus revenue estimates fall by 13% Dec 03
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 27 See more updates
Lexaria Bioscience Corp. Begins Dosing in its Phase 1B, 12-Week Chronic Study GLP-1-H24-4 Dec 19 Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board
Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide Dec 10
Chief Executive Officer recently bought US$51k worth of stock Dec 04
Consensus revenue estimates fall by 13% Dec 03
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 27
Lexaria Bioscience Corp. Highlights Expanding Therapeutic Benefits of GLP-1 Drugs Nov 27
Lexaria Bioscience Corp.'s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled Nov 26
Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study Nov 21 Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025
Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study Oct 25
Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1 Oct 22 Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million. Oct 17
Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million. Oct 16
Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million. Oct 15
Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology Oct 09
Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer Oct 01
Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3 Sep 27 Lexaria Bioscience Corp. Announces Chief Executive Officer Changes Sep 05
Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules Aug 30
First Results from Lexaria's Second GLP-1 Human Pilot Study Aug 27
Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study Aug 22
Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1 Aug 21
Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study Aug 19
Consensus revenue estimates fall by 24% Jul 19
Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study Jul 18
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 14
Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2 Jul 09
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study Jun 06
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study May 18
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study May 09
Consensus revenue estimates increase by 24% Apr 30
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study Apr 17
Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023) Apr 10
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer Mar 15
Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024 Mar 07
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1 Mar 06
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial Mar 02 Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million. Feb 17
Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million. Feb 16
Lexaria Bioscience Corp. Submits Investigational New Drug Application Jan 30
Consensus revenue estimates increase by 100% Jan 19
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program Jan 18
First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023) Jan 14
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream Jan 11
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform Jan 10
Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide Jan 05
Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update Dec 07
Consensus revenue estimates decrease by 20%, EPS upgraded Dec 01
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study Nov 29
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study Nov 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Nov 24 Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million. Nov 21
Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs Nov 01
Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) Oct 19
New major risk - Shareholder dilution Oct 05
Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1 Sep 22
Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress Aug 31
Consensus revenue estimates increase by 38%, EPS downgraded Aug 29
Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on Aug 11
Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on Aug 10
Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD Aug 03
Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products Jul 22
New major risk - Revenue and earnings growth Jul 21
New major risk - Financial position Jul 16
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 16
New major risk - Share price stability Jun 27
Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice Jun 25
Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study Jun 18 Lexaria Bioscience Corp. Announces Chief Financial Officer Changes
Lexaria Bioscience Corp. Discovers That DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers May 25
Lexaria Bioscience Corp. Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery May 19
Lexaria Bioscience Corp. Announces Batch Manufacturing of the DehydraTECH™-Processed Cannabidiol May 12 Lexaria Bioscience Corp. has completed a Composite Units Offering in the amount of $2.0007 million. May 11
Lexaria Bioscience Corp. has completed a Composite Units Offering. May 10
Lexaria Bioscience Corp. Human Clinical Nicotine Study Completes Dosing as Planned May 09
Consensus revenue estimates fall by 65% Apr 21
Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2022) Apr 16
Lexaria Bioscience Corp. Appoints Julian Gangolli as Strategic Advisor Jan 24
First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.35 loss in 1Q 2022) Jan 18
Lexaria Bioscience Corp.'s DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels Dec 22
Lexaria Bioscience Corp. Human Oral Nicotine Study Begins Dosing Dec 21
Lexaria Bioscience Corp. Enhances Performance Compared to Epidiolex in Seizure Study Program Nov 30
Full year 2022 earnings: EPS and revenues miss analyst expectations Nov 29
Price target decreased to US$15.00 Nov 16 Shareholder Returns LEXX US Pharmaceuticals US Market 7D -3.0% -1.9% -2.8% 1Y 65.5% 2.7% 24.1%
See full shareholder returns
Return vs Market: LEXX exceeded the US Market which returned 24.5% over the past year.
Price Volatility Is LEXX's price volatile compared to industry and market? LEXX volatility LEXX Average Weekly Movement 10.4% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: LEXX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LEXX's weekly volatility has decreased from 16% to 10% over the past year.
About the Company Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
Show more Lexaria Bioscience Corp. Fundamentals Summary How do Lexaria Bioscience's earnings and revenue compare to its market cap? LEXX fundamental statistics Market cap US$36.65m Earnings (TTM ) -US$5.80m Revenue (TTM ) US$464.28k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LEXX income statement (TTM ) Revenue US$464.28k Cost of Revenue US$4.82k Gross Profit US$459.46k Other Expenses US$6.25m Earnings -US$5.80m
Last Reported Earnings
Aug 31, 2024
Earnings per share (EPS) -0.33 Gross Margin 98.96% Net Profit Margin -1,248.25% Debt/Equity Ratio 0%
How did LEXX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 08:04 End of Day Share Price 2025/01/02 00:00 Earnings 2024/08/31 Annual Earnings 2024/08/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lexaria Bioscience Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ammar Shah Eight Capital Yi Chen H.C. Wainwright & Co. Michael Okunewitch Maxim Group
Show 1 more analysts 
